Source: Courthouse News Service
Merck is the only manufacturer licensed by the FDA to sell the mumps vaccine in United States, and if it could not show that the vaccine was 95 percent effective, it risked losing its lucrative monopoly, according to the complaint. That's why Merck found it critically important to keep claiming such a high efficacy rate according to a recently unsealed complaint.
Alabama-based Chatom Primary Care sued Merck on Monday, the week after the unsealing of a False Claims Act complaint two relators filed in 2010. Those relators, Stephen Krahling and Joan Wlochowski, were Merck virologists who claim in their unsealed complaint that they "witnessed firsthand the improper testing and data falsification in which Merck engaged to artificially inflate the vaccine's efficacy findings."
Krahling and Wlochowski claimed Merck's scheme caused the United States to pay "hundreds of millions of dollars for a vaccine that does not provide adequate immunization."